| Breast carcinoma is the most common malignant tumor in woman. Every year more than 900 000 new patients have been found around world. Nowdays the incidence of the breast carcinoma rises rapidly in our country and the age of the patients tends to younger. Because the pathogenesis of breast carcinoma is unknown, early diagnoses and integrative treatment are very important for the treatment of breast carcinoma. Since 80s the biological behavior of breast carcinoma has been studied the treatment pattern has been changed subsequently. According to clinic , pathology , some molecular biologic markers, prognosis and curative effect are monitored, integrative treatment becomes reasonable and individualization. Endocrine treatment of breast carcinoma were used after the estrogen receptor (ER) and progestogen receptor (PR) has been discovered in 1967. Except classical endocrine treatment marker such as ER, PR, estrogen-adjustment system (PS2) is a new mark of breast carcinoma. Objective: The expression of PS2, ER, PR were detected in 66 cases paraffin-embeded breast carcinoma tissue, in order to investigate their effect in biological behavior of breast carcinoma and to explicate the possible mechanism of endocrine treatment. Methods: 66 paraffin-embeded samples of breast carcinoma were obtained from the Department Pathology of Xinjiang MedicalUniversity and The Xinjiang Uigur Autonomous People Hospital. PS2 protein, ER and PR were detected by immunohistochemistry(S-P). All cases were diagnosed by pathologist. Results: The positive rate of PS2, ER and PR were 45.5%, 46.9% and 42.4%. The statistical data analysis shows that the expression of PS2 is not linked to age of the patients, size of tumor, stage of axillary node and status of menstruation (P=0.2794, P=0.3683, P=0.5237, P=0.6830). The expression of PS2 shows positive correlation with ER and PR(P=0.0001). PS2 positive rate of Five-year relapse-free survival(RFS) and Five-year overall survival (OS) were 73.3% and 86.7%. The rates were 47.2% and 58.3% in PS2 negative group. There is a statistical sense ( P=0.0316, P=0.0113) between the two groups. The expression of ER correlated with the rate of Five-year relapse-free survival(RFS) and Five-year overall survival (OS) (P=0.0216, p=0.0129). But the expression of PR didn't (P=0.0799, P=0.1221). The validity of endocrine treatment in patients with positive PS2 is higher than those of PS2 negative (p=0.0001). Conclusion: 1) The expression of PS2 is not linked to age of the patients, size of tumor, stage of axillary node and status of menstruation .2)The expression of PS2 related to the expression of ER. 3)The five-year survival rate of patients with positive PS2 is higher than that of patients with negative PS2. PS2 can be used as an independent marker to judge the prognosis. 4) PS2 can be used to forecast the effect of endocrine treatment for breast carcinoma. Combinating detection of PS2, ER and PR will be helpful in clinical treatment for breast carcinoma.
|
PDF Full Text Request